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1.1. Document Development Process
1.1.1. Writing Committee Organization
The writing committee was selected to represent
the American College of Cardiology (ACC) and included
a cardiovascular training program director, a car-
diology clinic director, early-career cardiovascular
disease (CVD) prevention experts, highly experienced
specialists representing both the academic and
community-based practice settings, a physician expe-
rienced in deﬁning and applying training standards
according to the core competencies structure that is
promulgated by the Accreditation Council for Graduate
Medical Education (ACGME) and American Board of
Medical Specialties (ABMS) and endorsed by the
American Board of Internal Medicine (ABIM), and a
fellow in training. The ACC determined that relation-
ships with industry or other entities were not relevant
to the creation of this general cardiovascular training
statement. Employment and afﬁliation details for the
authors and peer reviewers are provided in Appendixes
1 and 2, respectively, along with disclosure reporting
categories. Comprehensive disclosure information for
all authors, including relationships with industry and
other entities, is available as an online supplement to
this document.
1.1.2. Document Development and Approval
The writing committee developed the document,
approved it for peer review by individuals selected by
the ACC, and then addressed peer reviewers’ com-
ments. The document was revised and posted for,public comment from December 20, 2014, to January
6, 2015. Authors addressed the additional comments
from the public to complete the document. The ﬁnal
document was approved by the Task Force, COCATS
Steering Committee, and ACC Competency Manage-
ment Committee as well as ratiﬁed by the ACC Board
of Trustees in March 2015. This document is consid-
ered current until the ACC Competency Management
Committee revises or withdraws it.
1.2. Background and Scope
Atherosclerotic vascular disease, with its clinical
manifestations of myocardial infarction, stroke, and
peripheral vascular disease, is the world’s leading
cause of death, morbidity, and mortality and is,
therefore, themajor focus of training in prevention and
in the strategies recommended in this document. Other
disease prevention issues are dealt with in speciﬁc
sections. The missions of the ACC and the American
Heart Association have been to ensure optimal care to
those with or at risk for developing atherosclerotic
cardiovascular disease (ASCVD). The cardiovascular
specialist is expected to contribute signiﬁcantly to
treating and preventing CVD in the setting of a rapidly
growing ﬁeld of knowledge ranging from molecular
and cellular mechanisms to clinical outcomes. Over the
past 2 decades, there have been dramatic increases in
knowledge concerning speciﬁc risk factors, and
guidelines have been developed to address these fac-
tors relating to atherosclerosis, hypertension, throm-
bosis, and other forms of vascular dysfunction.
Despite the fact that clinical outcomes can be
improved by promoting favorable life habits and be-
haviors and by the proper use of drug treatment, the
application of preventive interventions in the clinical
practice of cardiovascular medicine is not optimal.
Part of this problem may be the insufﬁcient attention
that prevention education currently receives during
J A C C V O L . 6 5 , N O . 1 7 , 2 0 1 5 Smith, Jr. et al.
M A Y 5 , 2 0 1 5 : 1 7 5 4 – 6 2 COCATS 4 Task Force 2
1755cardiovascular fellowship. A recent survey of cardiovas-
cular fellowship programs revealed that most programs
do not meet current ACC/COCATS training recommenda-
tions for CVD prevention (1). In both the primary and
secondary prevention settings, ASCVD prevention must
no longer be peripheral to the practice of the cardiovas-
cular specialist. The cardiovascular specialist must
become proﬁcient in primary and secondary prevention of
ASCVD, having the ability to recommend speciﬁc primary
and secondary preventive measures and to identify pa-
tients with subclinical ASCVD who may beneﬁt from more
aggressive risk factor modiﬁcation. It is important for the
cardiovascular fellow to understand which therapies
promoted widely in practice and/or on the internet have a
strong evidence base and which do not.
It is imperative that cardiovascular training programs
provide the necessary education and training to promote
best practices among their trainees, who bear the re-
sponsibility to provide optimal preventive services to
their patients. This report outlines speciﬁc areas of
knowledge and skills necessary to achieve this goal and
also deﬁnes the required and recommended standards to
achieve this goal. The report updates previously pub-
lished standards for training cardiology fellows enrolled
in cardiac fellowship programs on the basis of changes in
the ﬁeld since 2008 (2) and as part of a broader effort to
establish consistent training criteria across all aspects of
cardiology. It also addresses the evolving framework of
competency-based medical education described by the
ACGME Outcomes Project and the 6 general competencies
endorsed by the ACGME and ABMS. For the purpose of
this document, all references to ASCVD prevention refer
to both primary and secondary prevention.
The background and overarching principles governing
fellowship training are provided in the COCATS 4 Intro-
duction, and readers should become familiar with this
foundation before considering the details of training in a
subdiscipline such as CVD prevention. The Steering
Committee and Task Force recognize that implementation
of these changes in training requirements will occur
incrementally over time.
For most areas of adult cardiovascular medicine, 3
levels of training are delineated:
n Level I training, the basic training required of
trainees to become competent consultant cardiologists,
is required of all fellows in cardiology, and can be
accomplished as part of a standard 3-year training
program in cardiology.
n Level II training refers to additional training in 1 ormore
areas that enables some cardiologists to perform or
interpret speciﬁc procedures or render more specialized
care for speciﬁc patients and conditions. This level of
training is recognized only for those areas in which anaccepted instrument or benchmark, such as a qualifying
examination, is available tomeasure speciﬁc knowledge,
skills, or competence. In the case of prevention, the Task
Force identiﬁed no speciﬁc competencies for Level II
training. Given the central importance of prevention to
managing patients with CVD, all competencies have
been identiﬁed as Level I (required for all fellows) or
relegated to advanced training postfellowship.
n Level III training—Although there are programs for
advanced training in prevention, such as may be
required to qualify as director of a clinical service,
research program, or both, there is, as yet, no formal
Level III certiﬁcation process for added qualiﬁcation in
prevention. Cardiologists whowish to focus their careers
on CVD prevention may wish to consider advanced
training outside of the ACGME-accredited training pro-
gram (see Section 4.2.2. Advanced Training).
2. GENERAL STANDARDS
ASCVD, or its antecedent risk factors, acquired at a young
age is often strongly related to poor lifestyle habits such as
unhealthy diet, sedentary behavior, and tobacco use. If
widely implemented, evidence-based population strate-
gies have the promise to reduce the burden of CVD risk
factors in the community and make preventive strategies
more effective for high-risk patients (3). As noted earlier,
training in CVD prevention should be an essential part of all
cardiovascular fellowship programs. Several important
statements and guidelines provide the basis for training in
the assessment and treatment of patients at risk of car-
diovascular events. These statements have been devel-
oped by organizations such as the ACC; American Heart
Association; and National Heart, Lung, and Blood Institute
and should be included as core references in training as
they become available and are updated (4–11). This evi-
dence base will be especially useful when cardiologists
begin practice after training and/or assume leadership
positions.
2.1. Faculty
There should be adequate faculty, both in number and
experience, to conduct training in preventive cardiovas-
cular medicine. It is also highly desirable for at least some
faculty to have expertise in vascular biology, atheroscle-
rosis, hypertension, disorders of lipid metabolism,
obesity and weight management, sleep medicine, diet
and nutrition, smoking cessation, diabetes mellitus,
thrombosis, clinical epidemiology, cardiac rehabilitation,
exercise physiology, clinical pharmacology, genetics and
pharmacogenomics, and the psychosocial aspects of CVD.
Ideally, speciﬁc faculty in the cardiovascular medicine
training program should be able to serve as topic area
experts in 1 or more of these areas. This is important
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models in preventive cardiovascular medicine. Mentoring
is important for cardiovascular trainees in their formative
years, and prevention-oriented role models should func-
tion in this capacity.
2.2. Facilities
Facilities should be adequate to ensure experience in
managing patients undergoing cardiac rehabilitation, as
well as to provide instruction on lifestyle measures such
as diet, weight loss, physical activity, psychosocial eval-
uation, and smoking cessation. Programs without access
to cardiac rehabilitation at the sponsoring institution may
be able to access community resources or arrange for
appropriate electives at other sites.
2.3. Equipment
Access to Web-based programs for assessing cardiovas-
cular risk is important. The availability of equipment
speciﬁed for noninvasive imaging (see COCATS 4 Task
Force 5: Echocardiography; Task Force 6: Nuclear Cardi-
ology; Task Force 7: Cardiovascular Computed Tomogra-
phy; and Task Force 8: Cardiovascular Magnetic
Resonance) is essential.
2.4. Ancillary Support
Ancillary support to provide counseling on diet, exercise,
weight loss, smoking cessation, and managing psychoso-
cial risk factors should be available.
3. TRAINING COMPONENTS
3.1. Didactic Program
Didactic instruction may take place in a variety of for-
mats, including, but not limited to, lectures, conferences,
journal clubs, grand rounds, clinical case presentations,
and patient safety or quality improvement conferences.
The importance of clinical history should be taught on a
regular basis and emphasized in patient-related confer-
ences. Clinical history includes family history; assessment
of diet, physical activity, ﬁtness, and other lifestyle
habits; physical examination; and electrocardiographic
manifestations and ﬁndings from other noninvasive im-
aging tests used to identify subclinical atherosclerosis.
3.2. Clinical Experience
Rotation on general cardiovascular services is an essential
component of training in CVD prevention. Level I trainees
should gain ﬁrsthand experience in treatment strategies
for primary and secondary prevention, as well as in
management of complex dyslipidemia and advanced
hypertension.
Training in CVD prevention should involve prevention
across the risk continuum for patients of varying age,sex, and ethnicity. It should include patients who have
undergone revascularization, cardiac transplantation,
and other complex cardiovascular procedures. Given the
importance of CVD as a global threat, training obtained
outside of the primary institution, including interna-
tional experiences, can provide valuable insight to
trainees on the challenges involved in reducing cardio-
vascular risk in less technologically developed health
systems.
3.3. Hands-On Experience
Hands-on experience is important for training in CVD
prevention. Trainees in cardiology should spend 6 to 12
months devoted to managing patients with advanced
atherosclerosis, heart failure, valvular heart disease,
arrhythmia, dyslipidemia, obesity, sedentary lifestyle,
and hypertension. Additionally, trainees should partici-
pate in delivering cardiac rehabilitation in the appropriate
inpatient and outpatient environments to acquire the
core competencies. Opportunities to practice in disease
prevention or wellness centers and in pediatric and
adolescent prevention clinics may add valuable perspec-
tive and education on issues facing patients with less-
advanced disease states.
4. SUMMARY OF TRAINING REQUIREMENTS
4.1. Development and Evaluation of Core Competencies
Training and requirements in CVD prevention address the
6 general competencies promulgated by the ACGME/
ABMS and endorsed by the ABIM. These competency do-
mains include: medical knowledge, patient care and
procedural skills, practice-based learning and improve-
ment, systems-based practice, interpersonal and
communication skills, and professionalism. The ACC has
used this structure to deﬁne and depict the components
of the core clinical competencies for cardiology. The
curricular milestones for each competency and domain
also provide a developmental roadmap for fellows as they
progress through various levels of training and serve as an
underpinning for the ACGME/ABIM reporting milestones.
The ACC has adopted this format for its competency and
training statements, career milestones, lifelong learning,
and educational programs. Additionally, it has developed
tools to assist physicians in assessing, enhancing, and
documenting these competencies.
Table 1 delineates each of the 6 competency domains
as well as their associated curricular milestones for
training in CVD prevention. The milestones indicate the
stage of fellowship training (12, 24, or 36 months, and
additional time points) by which the typical cardiovas-
cular trainee should achieve the designated level.
Because programs may vary with respect to the sequence
TABLE 1 Core Competency Components and Curricular Milestones for Training in Cardiovascular Disease Prevention
Competency Component Milestones (Months)
MEDICAL KNOWLEDGE 12 24 36 Add
1 Know the structure of the normal artery and the basic vascular biology of atherosclerotic vascular disease. I
2 Know the principles of genetics as applied to cardiovascular disease and pharmacogenomics as applied to
cardiovascular therapy.
I
3 Know the impact of family history on disease risk and utility of family screening in cardiovascular disease prevention. I
4 Know the clinical epidemiology of cardiovascular disease, including incidence/prevalence, sex and ethnic differences,
and the inﬂuence of traditional risk factors and demographics on outcomes.
I
5 Know the principles for implementation both of individual and population-based cardiovascular disease prevention. I
6 Know the major tools to assess both lifetime and 10-year risks of a ﬁrst cardiovascular event and inﬂuence
primary prevention measures.
I
7 Know the evidence for incremental beneﬁt over a traditional risk-based approach, as well as the advantages,
disadvantages, and limitations of screening methods to assess subclinical atherosclerosis (including biomarkers,
coronary calciﬁcation, carotid intima-media thickness, and ankle-brachial index).
I
8 Know the effects of diabetes mellitus, obesity, hypertension, lipid disorders, physical inactivity, and tobacco use
on the development and progression of atherosclerosis, and their treatment strategies.
I
9 Know the physiology and assessment of diabetes mellitus and principles of its management and comanagement
in patients with cardiovascular disease.
I
10 Know the physiology, assessment, and management of lipid disorders, including in special populations. I
11 Know the physiology, presentation, evaluation and management of hypertensive disorders, including refractory
hypertension.
I
12 Know the principles of nutrition and obesity assessment and management, including the roles of pharmacotherapy
and bariatric surgery.
I
13 Know the roles and management principles for behavioral and psychosocial contributions to cardiovascular disease. I
14 Know the principles and roles of exercise physiology, physical activity counseling, and cardiac rehabilitation. I
15 Know the tools and principles for managing and counseling regarding tobacco cessation. I
16 Know the effects of systemic diseases and their treatments (including renal, hepatic, inﬂammatory, and
autoimmune-related disorders) on cardiovascular risk factors and their management.
I
17 Know adverse effects of obstructive and central sleep apnea on the incidence and control of hypertension,
atrial ﬁbrillation and other arrhythmias, congestive heart failure, and atherosclerosis.
I
18 Know the indications for noninvasive screening for carotid artery disease, abdominal aortic aneurysm, and
peripheral vascular disease.
I
19 Know the impact of reproductive stages, pregnancy, and hormonal treatment for reproductive disorders on
cardiovascular risk.
I
20 Know the principles of antithrombotic therapy in cardiovascular disease. I
21 Know the pharmacology, indications, contraindications, and interactions of medications commonly used in
cardiovascular disease prevention and therapy (e.g., antithrombotic agents, antihypertensive agents,
lipid-lowering agents, agents used in diabetes mellitus management, and agents used in cessation of tobacco).
I
EVALUATION TOOLS: chart-stimulated review, direct observation, and in-training examination.
PATIENT CARE AND PROCEDURAL SKILLS 12 24 36 Add
1 Skill to perform global risk assessment and appropriately utilize diagnostic testing—both in patients at risk for
and those with prior cardiovascular events or diagnoses.
I
2 Skill to evaluate a patient’s family history and appropriately recommend family screening. I
3 Skill to identify patients who may have common systemic disorders that affect cardiovascular disease diagnosis
and treatment such as sleep apnea and thyroid disorders.
I
4 Skill to implement and prescribe lifestyle approaches for the prevention and treatment of hypertension,
dyslipidemia, tobacco use, obesity, and diabetes mellitus.
I
5 Skill to assess physical activity patterns and exercise capacity and provide physical activity counseling and
exercise prescription, as well as counseling on whether to return to sports.
I
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TABLE 1 Core Competency Components, continued
Competency Component Milestones (Months)
PATIENT CARE AND PROCEDURAL SKILLS 12 24 36 Add
6 Skill to identify patients who will beneﬁt from low-density lipoprotein apheresis. I
7 Skill to identify patients for whom antiplatelet therapy is indicated. I
8 Skill to identify and address factors that contribute to nonadherence to treatment regimen. I
9 Skill to utilize individualized risk–beneﬁt assessment in the management of patients and adapt prevention
strategies to patients with speciﬁc comorbidities (e.g., diabetes mellitus, chronic kidney disease, arthritis).
I
10 Skill to appropriately integrate new medical information into patient care. I
EVALUATION TOOLS: chart-stimulated recall, direct observation, and registry and/or hospital program quality data.
SYSTEMS-BASED PRACTICE 12 24 36 Add
1 Practice in a manner that best balances appropriate utilization of ﬁnite resources with the net clinical beneﬁt
for the individual patient.
I
2 Utilize an interdisciplinary team approach for disease management. I
3 Coordinate patient care among healthcare providers, including transfer of care. I
4 Identify and address ﬁnancial, cultural, and social barriers to treatment implementation and adherence. I
5 Appropriately utilize specialty care for patients with advanced or complex diabetes mellitus, complex lipid
disorders, refractory hypertension, obesity, depression, or sleep apnea.
I
6 Appropriately utilize disease management tools and protocols as an aid in the management of patients with
high risk-factor burden and established chronic diseases.
I
EVALUATION TOOLS: direct observation and multisource evaluation.
PRACTICE-BASED LEARNING AND IMPROVEMENT 12 24 36 Add
1 Identify knowledge and performance gaps and engage in opportunities to achieve focused education and
performance improvement.
I
2 Utilize point-of-service resources to enhance adherence to guidelines and protocols and obtain new information
from clinical trials and professional societies.
I
EVALUATION TOOLS: chart-stimulated recall, direct observation, registry and/or hospital program quality data, and reﬂection and
self-assessment.
PROFESSIONALISM 12 24 36 Add
1 Know and promote adherence to guidelines and appropriate use criteria. I
2 Demonstrate respect for individuals with lifestyle disorders such as obesity and tobacco use. I
3 Practice prevention in your personal lifestyle and promote a culture of healthy lifestyle choices and physical
activity in your work environment and community.
I
EVALUATION TOOLS: conference presentation, direct observation, and multisource evaluation.
INTERPERSONAL AND COMMUNICATION SKILLS 12 24 36 Add
1 Communicate with and educate patients and families across a broad range of cultural, ethnic, and socioeconomic
backgrounds regarding appropriate risk factor modiﬁcation.
I
2 Communicate in ways that patients and families can understand the evidence on which recommendations
are based.
I
3 Evaluate a patient’s health literacy and appropriately adapt counseling strategies and tools. I
4 Communicate effectively with patients, families, and referring physicians. I
EVALUATION TOOLS: direct observation and multisource evaluation.
Add ¼ additional months beyond the 3-year cardiovascular fellowship.
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1759of clinical experiences provided to trainees, the mile-
stones at which various competencies are reached may
vary as well. Level I competencies may be achieved at
earlier or later time points. The table also describes
examples of evaluation tools suitable for assessing
competence in each domain.
4.2. Training Requirements
Training for CVD prevention should be incorporated
into all aspects of a cardiovascular training program.
Given the importance of prevention in managing pa-
tients with CVD, all competencies to be obtained during
the 3-year fellowship program are denoted as Level I,
required for every trainee. Advanced postfellowship
training can be obtained to acquire a body of knowledge
and career pathway to specialize in CVD prevention,
leading to a leadership focus in this ﬁeld. The speciﬁc
training elements required are discussed in the
following sections.
4.2.1. Level I Training Requirements
Clinical trials have proven that strategies aimed at
appropriately detecting and modifying risk factors can
slow progression of atherosclerosis and hypertension
and reduce the occurrence of clinical events in both
primary and secondary prevention settings. More
recently, it has been shown that atherosclerosis can be
stabilized or even modestly reversed with an associated
reduction in undesirable clinical outcomes. Finally, the
growing knowledge base of cardiovascular molecular
genetics has potentially important implications for the
future clinical practice of preventive cardiovascular
medicine. Level I training is required of all cardiovas-
cular specialists and includes the milestones outlined in
Table 1. It is important to realize that this list of key
measures should not be considered all-inclusive. The
ﬁeld of cardiovascular prevention is ever-changing, as
epidemiologic and clinical trial data accumulate.
Training programs should be oriented toward imple-
menting the most up-to-date guidelines for all risk fac-
tors in CVD prevention.
To achieve this level of competency, the Task Force
believes the typical fellow will require 1 month of dedi-
cated training in ASCVD prevention. A potential mecha-
nism to obtain this level of training could be participation
in a 1-month (or longer) rotation dedicated to preventive
cardiovascular medicine (Table 1). Acceptable alternatives
include a 3-month (or longer) clinical cardiovascular
rotation that allows concomitant exposure to a compre-
hensive cardiovascular rehabilitation program at least
1 day each week. This would allow incorporation of a
broad range of preventive approaches in addition to the
predominant rehabilitation focus of physical exercise.
Ideally, the 1-month rotation should include weeklyattendance at a cardiac rehabilitation program, diabetes
mellitus or endocrinology clinic, hypertension clinic, and
lipid disorders clinic. Another alternative includes
obtaining training in these areas through consultative,
inpatient, and outpatient rotations, with additional
didactic sessions, such as monthly lectures focusing on
cardiovascular prevention topics. If the latter approach is
taken, the time allotted should be equivalent to at least
1 month of full-time training. Training program directors
may also consider supplementing clinical experiences
with short courses devoted exclusively to preventive
cardiovascular medicine or risk factor evaluation and
management.
4.2.2. Advanced Training Requirements
The most effective preventive cardiovascular medicine
services incorporate the skills and knowledge of multiple
providers, including cardiovascular physicians, nurses,
nurse practitioners, physician assistants, dietitians, sleep
and behavioral medicine specialists, and exercise physi-
ologists. They operate on principles of interdisciplinary
teamwork and use systemic approaches to patient care.
Although such programs are more effective than routine
cardiovascular practice, few training programs offer op-
portunities to learn these new skills. Programs interested
in offering advanced training should incorporate these
new concepts into the training program, and trainees
interested in advanced training should seek programs
that offer these approaches to patient care (12). The type
of skills developed in such advanced training programs
might include competency in managing patients using
low-density lipoprotein apheresis; leadership training to
serve as director of a preventive cardiovascular medicine,
hypertension, or lipid service, a cardiac rehabilitation
program, or vascular or sleep medicine laboratory; or, in
the case of a trainee, obtaining a master’s degree in public
health, clinical epidemiology, or outcomes research. These
competencies are beyond the Level I training in preventive
cardiovascular medicine included in a cardiovascular
fellowship program. Fellows interested in advanced
training may wish to consider training and certiﬁcation
through participation in various subspecialty societies
(e.g., the American Association of Cardiovascular and
Pulmonary Rehabilitation, American Academy of Sleep
Medicine, American Society of Hypertension, National
Lipid Association, Association for the Treatment of
Tobacco Use and Dependence, and The Obesity Society/
American Board of Obesity Medicine) or to participate in
additional training in CVD prevention during 3rd year
electives or during a 4th year of training in non–ACGME
training programs in CVD prevention (12). Speciﬁc compe-
tencies for prevention specialists and medical directors of
cardiac rehabilitation programs have been published pre-
viously (5,13).
Smith, Jr. et al. J A C C V O L . 6 5 , N O . 1 7 , 2 0 1 5
COCATS 4 Task Force 2 M A Y 5 , 2 0 1 5 : 1 7 5 4 – 6 2
17605. EVALUATION OF COMPETENCY
Evaluation tools in CVD prevention include direct obser-
vation by instructors, in-training examinations, case log-
books, conference and case presentations, multisource
evaluations, trainee portfolios, simulation, and reﬂection
and self-assessment. Case management, judgment,
interpretation, and bedside skills must be evaluated in
every trainee. Quality of care and follow-up; reliability;
judgment, decisions, or actions that result in complica-
tions; interaction with other physicians, patients, and
laboratory support staff; initiative; and the ability to
make appropriate decisions independently should be
considered. Trainees should maintain records of partici-
pation and advancement in the form of a Health
Insurance Portability and Accountability Act (HIPAA)–
compliant electronic database or logbook that meets
ACGME reporting standards and summarizes pertinent
clinical information (e.g., number of cases, dates, and
patient identiﬁers such as medical record number and
faculty supervisor).The ACC, American Heart Association, and American
College of Physicians published a curriculum on CVD
prevention (5). The ACC offers an Adult Clinical Cardiol-
ogy Self-Assessment Program (ACCSAP) that includes in-
formation on preventive cardiovascular medicine, and
other societies offer similar self-assessment programs
(e.g., the National Lipid Association Self-Assessment
Program). Training directors and trainees are encour-
aged to incorporate resources such as these in the course
of training, to utilize in-service examinations, and to
ensure trainees (and faculty) have acquired appropriate
knowledge of preventive cardiovascular medicine.
Under the aegis of the program director, the faculty
should record and verify each trainee’s experiences,
assess performance, and document satisfactory achieve-
ment. The program director is responsible for conﬁrming
experience and competence and reviewing the overall
progress of individual trainees with the Clinical Compe-
tency Committee to ensure achievement of selected
training milestones and identify areas in which additional
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